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Abstract 
Exclusion of nausea (N) and vomiting (V) from detailed consideration as symptoms of 
COVID-19 is surprising as N can be an early presenting symptom. We examined the 
incidence of NV during infection before defining potential mechanisms. We estimate that 
the overall incidence of nausea (median 10.5%), although variable, is comparable to 
diarrhoea. Poor definition of N, confusion with appetite loss, and reporting of N and/or V as 
a single entity may contribute to reporting variability and likely underestimation. We 
propose that emetic mechanisms are activated by mediators released from the intestinal 
epithelium by SARS-CoV-2 modulate vagal afferents projecting to the brainstem and after 
entry into the blood, activate the area postrema (AP) also implicated in anorexia. The 
receptor for spike protein of SARS-CoV-2, angiotensin 2 converting enzyme (ACE2), and 
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transmembrane protease serine (for viral entry) are expressed in upper GI enterocytes, 
ACE2 is expressed on enteroendocrine cells (EECs), and SARS-CoV-2 infects enterocytes but 
not EECs (studies needed with native EECs). The resultant virus-induced release of epithelial 
mediators due to exocytosis, inflammation and apoptosis provides the peripheral and 
central emetic drives. Additionally, data from SARS-CoV-2 shows an increase in plasma 
angiotensin II (consequent on SARS-CoV-2/ACE2 interaction), a centrally (AP) acting emetic, 
providing a further potential mechanism in COVID-19. Viral invasion of the dorsal brainstem 
is also a possibility but more likely in delayed onset symptoms. Overall, greater attention 
must be given to nausea as an early symptom of COVID-19 and for the insights provided into 
the GI effects of SARS-CoV-2. 
Keywords: ACE2, angiotensin converting enzyme 2, angiotensin II, COVID-19, 
dexamethasone, diarrhoea, enteroendocrine cells, nausea, SARS-CoV-2, TMPRSS2, vomiting 
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Introduction. 
In addition to the prominent respiratory and pyrexic symptoms of severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2)1, the symptom complex can include symptoms 
associated with the digestive tract including anorexia, nausea, vomiting and diarrhoea. Of 
these, diarrhoea has received the most attention in the original literature2-6, commentaries7-
9 and reviews10-12. Surprisingly, nausea and vomiting have not been discussed in detail. This 
is a serious omission as nausea and vomiting can be the presenting symptoms, as 
exemplified by the first cases of COVID-19 in the USA13 and China2. Initially the occurrence of 
nausea and vomiting was reported to be “uncommon” with an incidence of <4%7 but more 
recently their prevalence has been described as “common”11. Superficially at least, the 
incidence of nausea and vomiting seems comparable to that for diarrhoea (~5% -6% in some 
systematic studies14, 15); ~10% in others10; some studies report incidences for diarrhoea of 
≥30%3, 11. 
It is important to understand the incidence of nausea and vomiting during COVID-19 and the 
mechanisms by which this can occur. Patients with digestive tract symptoms, including 
nausea, vomiting and diarrhoea, may have delayed hospital admission and a worse clinical 
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outcome than those without16. It has been argued3 that the value of diarrhoea as a clinical 
symptom in the diagnosis and spread of COVID-19 may be underestimated, particularly as 
digestive tract symptoms may precede respiratory ones11. However, nausea is an acute 
onset, early warning of a problem in the upper digestive tract (primarily stomach and small 
intestine), which can receive air when swallowing, and is a component of the body’s 
epithelial defences, triggered in the “natural” world by ingested toxins17. This mean that 
nausea may be the first indication of gastrointestinal (GI) infection by SARS-CoV-2; 
interestingly “virus” is the Latin word for “poison”. Given the current paucity of knowledge 
we first address key questions about COVID-19 in relation to the prevalence of nausea and 
vomiting and then discuss plausible mechanisms. 
How good is the epidemiological data on the incidence of nausea and vomiting in COVID-
19?  
Nausea is a self-reported sensation but unless it is clearly defined for the patient, 
particularly in epidemiological studies and drug trials, there is a potential for confusion. 
Firstly, reporting of the symptom needs to be specifically requested to avoid the practice of 
merging the terms nausea, retching and vomiting into a single adverse event. Secondly, the 
patient will base their understanding of the word on what they have been told nausea feels 
like (most likely originally by a parent or a clinician) or their previous experience of nausea 
(most likely in motion sickness); this may also be influenced by cultural and linguistic 
differences. Thirdly, symptoms which can occur with nausea or independently such as lack of 
desire to eat, dyspepsia and epigastric discomfort short of overt pain may or may not be 
reported as nausea. These problems are compounded by the lack of a validated diagnostic 
biomarker for nausea although elevated plasma vasopressin and gastric dysrhythmia are 
associated with nausea18, 19.  
It has been proposed to use pictograms to improve digestive tract symptom assessment,20 
helping to minimize linguistic and translation issues – particularly important when assessing 
comparability of symptom reporting from a global pandemic where cultural perceptions and 
understanding of nausea may complicate accurate reporting. 
  The literature contains multiple definitions of nausea (see Table 1.118 for 30 definitions 
from the literature) which may be associated with different body areas (e.g. head, chest, 
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epigastrium)19. Here, we define nausea as “a self-reported, unpleasant sensation associated 
with the desire to vomit or the feeling that vomiting is imminent”18.  Although vomiting is 
easier to define (the forceful oral expulsion of upper digestive tract contents) it may be 
identified incorrectly and used interchangeably with retching (unproductive, forceful, 
externally visible, rhythmic contractions of thoracic and abdominal muscles usually 
preceding  vomiting21) and can be confused with intense gastroeophageal reflux. Nausea 
and vomiting can be reported as a single entity (nausea or vomiting1, nausea and/or 
vomiting22) although they are a sensation and motor act respectively.  
However, in reviewing the publications where data on the incidence of both nausea and 
vomiting have been collected it is clear that both can be an early “acute” symptom of 
COVID-19. Detailed data needs to be collected on the incidence of N & V at all stages of 
SARS-CoV-2 infection. We highlight four important issues related to the epidemiology. 
1. Nausea and vomiting need to be reported separately. In the studies where 
this has been done the incidences are either identical (e.g., 1% vs. 1% 1; 5% 
vs. 5%23; 3.7% vs. 3.7% 24) or higher than for vomiting (e.g., 10.1% vs. 3.6%; 
17.3% vs. 5.0%; 26.4% vs. 15.4 %  25-27 A similar equivalence in the incidence 
of nausea and vomiting is seen for SARS and MERS where the overall 
incidences of both are higher at ~20%12. Although  the data on COVID-19 
are  limited, the incidence of nausea appears to be highly variable with a 
range of 1%-30% 23, 26 (Figure 1). Our literature analysis of 41 studies of 
>12000 COVID-19 patients (including children28) in which nausea and/or 
vomiting data was reported, showed that the median incidence of nausea 
was 10.5% and that of diarrhoea reported in the same studies was 11%; the 
latter comparable to the prevalence of 10.4% reported in a recent 
systematic review29 but higher than in some other studies14, 15. These 
findings support the view that nausea and diarrhoea should be given equal 
prominence as symptoms. Notably, the median incidence of vomiting was 
7%  (Figure 1), an incidence comparable with the 6.9% reported for 
abdominal pain in a systematic review/meta-analysis29. It should be noted 
that as far as we are aware separate detailed data on the incidence of 
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nausea and vomiting in males and females has not been published and 
apart from the studies in children there is no detailed age-stratified 
symptom data. 
 
 2. What is the co-occurrence of nausea and vomiting with other digestive tract 
symptoms in COVID-19? Considering the likely effects of SARS-CoV-2 on the 
digestive tract (discussed below) a relationship between symptoms such as 
nausea/vomiting and diarrhoea would not be unexpected but identifying the 
time of onset of each post-infection is essential to assessing their relative 
relevance for diagnosis.  Without data on individual patients it is not possible to 
draw firm conclusions but some studies have begun to report the incidence of 
single and groups of symptoms. For example, nausea or vomiting with 
diarrhoea has been reported with an incidence of 4.9%30 and 4.3%22. In the 
forty-one clinical studies analyzed above, twenty-seven reported the incidence 
of nausea/vomiting and diarrhoea with our analysis showing a correlation 
(Spearman R, 0.8 and 0.7). Identification of the temporal expression of 
symptoms and their clustering will be essential for classification of the ways in 
which SARS-CoV-2 infection can present, and to quickly recognize evolving  
patterns of presentation, as this may be a reflection of viral load and its relative 
impact on the respiratory and digestive tracts, and subsequently the brain (see 
below for discussion). One study noted that patients with nausea and vomiting, 
and diarrhoea were more likely to have fever, than those with either digestive 
symptom alone31. Finally, it is recognized that type II diabetes is a risk factor for 
COVID-1932. The frequent occurrence of gastroparesis in diabetic patients33 
may make this group either more sensitive to the nausea and vomiting during 
SARS-CoV-2 infection or result in more intense symptoms. 
 
3. What is the severity of the nausea? To date, the published studies have 
only reported on the presence or not of nausea and vomiting, with no 
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descriptions of their severity, comparable to those used routinely to assess 
these symptoms as side-effects of anti-cancer chemotherapy34. A study of 
almost 2000 patients reported that GI symptoms (predominantly diarrhoea, 
nausea, vomiting, and abdominal pain) were “judged to be mild” in 74% of 
patients35 which could imply it was more severe in the remaining 26%. 
Additionally, there is a paucity of data on the temporal pattern of nausea 
and vomiting during the course of the disease. One publication commented 
that digestive symptoms (including vomiting but not nausea) became more 
pronounced as the severity of disease increased16.  In another, the 
prevalence of nausea or vomiting was twice as high in hospitalized patients 
(not ICU) compared with the emergency department (10% [6.2-15.8] vs. 
22.6% [19.5-26.1]) but interestingly reduced to 10.2% (6.9-14.7%) in 
patients in intensive care36. A recent commentary on the research priorities 
in the digestive manifestations of COVID-1937 called for “a more rigorous 
and systematic assessment of the prevalence, spectrum and severity of 
digestive  manifestations”. We agree but strongly argue that nausea should 
be included as part of the symptom cluster. Similarly, the utility of mobile 
technology for collecting real-time data on symptoms of COVID-19 (see 
below) has been demonstrated38, 39  but the symptom check list included in 
the Supplementary data38 included diarrhoea, abdominal pain and skipping 
meals, not nausea or vomiting. Such mobile technology is ideally suited to 
obtain data on the presence and intensity of nausea with a high temporal 
resolution and to investigate changing patterns of symptom expression.  
4. The relationship between nausea and appetite. A few studies report 
lack/loss of appetite or poor/low appetite, with an incidence apparently 
higher than that of nausea (23.2%, 49.5%, 40%)16, 22, 31. Of these studies, 
some16, 31 did not report nausea but others22 reported ‘nausea and/or 
vomiting’ with an incidence of 12% but the percentage of patients with 
either nausea or vomiting or both was not reported.  Whilst reduced 
appetite is a common symptom of infection it can also be secondary to 
nausea as indicated by a pre-clinical study of the cytokine growth 
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differentiation factor15 (GDF15)40 demonstrating anorexia by induction of 
nausea and/or engaging with emetic mechanisms; this is also the case in 
cancer chemotherapy34. The incidence of anorexia in COVID-19 patients in 
intensive care units is reported to be ~2x that of patients who were not41. 
As described above, it is likely that some patents will report loss of appetite 
when in reality they have nausea, emphasizing the need for clarity and 
consistency of definitions when collecting data on nausea (as proposed for 
diarrhoea3). The recent study of real-time tracking of self-reported 
symptoms38 identified “skipped meals” as the symptom with the second 
highest odds ratio of SARS-CoV-2 infection after loss of smell; nausea as a 
potential underlying cause of skipping meals should be investigated further. 
Although children become infected with COVID-19 they appear to be 
relatively asymptomatic in relation to adults, but there are reports of 
vomiting28, 42. However, young children may not be capable of verbalizing 
nausea and food refusal in children has been argued to be an indicator of 
nausea43. 
In summary, more attention should be given to recognizing nausea, which as we highlighted 
above must be clearly defined to avoid confusion, as a potential early symptom of COVID-19 
particularly when collecting epidemiological data. It is plausible that infected subjects who 
do not have the classical symptoms (fever and persistent cough and loss of taste/smell) may 
have initially experienced mild, transient nausea, and dismissed it. Accordingly, 
asymptomatic but SARS-CoV-2 positive individuals, many of whom are likely to be in the 
younger age groups, need to be investigated to determine if they have recently had an 
episode of nausea which was dismissed or ascribed to “food poisoning”. Thus, since nausea 
is an early alerting symptom of a challenge (toxic food and chemicals, bacterial toxin, virus) 
to the upper digestive tract, this may be an overlooked initial symptom of SARS-CoV-2 
infection. Such studies are also important because if nausea is an early symptom of COVID-
19 the vomiting which may follow would lead to ejection of aerosolized, viral contaminated 
vomit, as occurs in patients infected with norovirus44. 
Finally, it is important to recognize that subjects with nausea (primarily studied in motion 
sickness) may have a reduction in cutaneous blood flow to the forehead manifest as 
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“pallor”45  associated with “cold sweating”18. As the forehead is a common site at which 
temperature is taken, nausea induced by SARS-CoV-2 could be a factor confounding 
detection of raised core temperature by a single time point measurement of forehead 
temperature alone. 
 
How could SARS-CoV-2 induce nausea and vomiting? 
There are no formal studies at present so we have reviewed the effects of SARS-CoV-2 (and 
other coronaviruses) on the digestive tract in the light of knowledge of the established 
mechanisms of nausea and vomiting; this is the same approach that has been used to 
understand the pathogenesis of other symptoms (e.g. diarrhoea10). 
SARS-CoV-2 can readily access the digestive tract by several routes (Figure 2). We 
hypothesize that SARS-CoV-2 would induce acute (first few days post-infection) nausea and 
vomiting by causing the release of key hormones from the enteroendocrine cells (EECs) in 
the mucosa of the upper GI tract or after gaining direct entry into the blood, by acting 
directly within the brainstem. 
1. Pathways of nausea and vomiting 
Induction of nausea and vomiting from the digestive tract occurs via two main 
mechanisms18, 46:  
a) Activation of abdominal vagal afferents, either mechanoreceptors located in the 
muscle layers or afferents terminating in close apposition to the mucosa activated by 
neuroactive agents (e.g. 5-hydroxytrytamine [5-HT], substance P [SP], cholecystokinin 
[CCK]) released locally from the EECs to act at receptors expressed by afferent nerve 
terminals. Among the EEC cells the enterochromaffin cells (EC) in the duodenum and 
jejunum contain most of the 5-HT present in the body of humans and other 
mammals which when released by chemical (e.g. cancer chemotherapy, oral emetics) 
and pathological (e.g. inflammation) stimuli has a particularly prominent role in 
induction of emesis via activating abdominal vagal afferent nerve terminals47(Figure 
2) 
b) Release of neuroactive agents into the hepatic portal vein and subsequently the 
systemic circulation to act on the area postrema, a circumventricular organ located at 
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the caudal extremity of the fourth ventricle where the blood-brain and cerebrospinal 
fluid-brain barriers are relatively permeable (Figure 2). These agents may originate 
from the EECs (e.g. glucagon like-1 peptide [GLP-1], CCK) but also as cytokines from 
inflamed or damaged GI epithelia. 
Both the vagal afferents and area postrema efferents activate the nucleus tractus solitarius 
(NTS), subjacent to the area postrema in the brainstem which in turn activates the visceral 
and somatic motor pathways for vomiting elsewhere within the brain stem and also sends 
projections to higher brain regions generating the sensation of nausea18, 19 (Figure 2). The 
release of neuroactive agents from EECs is implicated in both acute, early onset nausea and 
vomiting when the release is by Ca++-mediated exocytotic mechanisms and in more 
protracted responses when inflammatory-like responses and cell damage are implicated34. 
The likelihood that nausea requires less intense activation of the above pathways than does 
vomiting, means that greater emphasis should be given to nausea rather than vomiting as an 
initial symptom of digestive tract infection by SARS-CoV-2.  
2. ACE2 in the digestive tract, viral entry, nausea and vomiting by peripheral actions of 
SARS-CoV-2.  
Release of neuroactive agents from the digestive tract acting locally (vagal afferents) and 
systemically (area postrema) has been implicated in nausea and vomiting induced by toxins 
ingested with food, therapeutic drugs and bacteria46, 48-50. We know of only one study 
investigating a direct link between viral infection and the mechanisms of nausea and 
vomiting. The virus commonly responsible for infantile gastroenteritis (vomiting and 
diarrhea are symptoms), rotavirus, has been shown to infect and replicate in EC cells (from 
midgut carcinoid tumour and GOT1 cells), increasing intracellular [Ca++] and secretion of 5-
HT from the EC cells. Notably, 5-HT secretion increased by 6h after infection51. Using 
supernatant from viral infected MA104 cells, secretion of 5-HT from GOT1 and primary EC 
tumour cells occurred within 60min demonstrating that it was most likely due to viral 
protein(s) from infected cells rather than due to cell replication. Cell [Ca++] was elevated and 
5-HT secreted in response to the enterotoxic glycoprotein NSP4 previously shown to be 
secreted from human intestinal cells infected with rotavirus. In mice infected with rotavirus 
there was co-localization between viral proteins and 5-HT-containing EC cells and Fos 
immunohistochemistry showed intense activation of the NTS suggestive of vagal afferent 
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activation (see above). The same laboratory also demonstrated an ability of adenovirus 41, a 
cause of acute gastroenteritis with diarrhoea and vomiting, to increase 5-HT release from 
human EC cells52. 
Finally, it is worth noting that rotavirus infected infant mice displayed diarrhoea which was 
treated with the 5-HT3 receptor antagonist ondansetron, which also improved weight gain 
and  interestingly, attenuated viral shedding53. The latter may be of clinical value as 
ondansetron and other 5-HT3 antagonists are widely available for treatment of acute cancer 
chemotherapy induced nausea and vomiting 46. 
So, what of SARS-CoV-2? The angiotensin converting enzyme II (ACE2) protein is the receptor 
for the spike protein of SARS-CoV-2, providing a key component of the entry route for the 
virus into cells as is the case for SARS and MERS54, 55. Cellular serine protease 
transmembrane protease serine-2 (TMPRSS2) is required together with ACE2 for viral entry 
56, 57. Early human and rodent studies identified ACE2 in the digestive tract and particularly 
the ileum but also other regions of the small intestine54, 58, 59. More recent studies have 
confirmed the presence of ACE2 in human small intestine, including the duodenum, and 
some have shown expression of TMPRSS23, 60-62. In particular, the studies have identified 
ACE2 and TMPRSS2 in “absorptive enterocytes” and more generally “epithelial cells”6, 61. 
Expression of ACE2 mRNA has also been shown in the relatively sparse EECs within the 
enterocytes of human stomach and ileum63, although a transcriptomic and proteomic study 
of human and mouse intestinal EECs did not highlight ACE2 as among the most highly 
expressed receptors in either species64. These data find some concordance with a study of 
mouse small intestine appearing to indicate that although the ACE2 receptor was highly 
expressed in enterocytes, there was no expression in “endocrine” cells (although the viral 
receptor HCoV-229E (ANPEP) was present in this population)3.  However, mice lack the 
ability to vomit and other differences between human and rodent digestive tract suggest 
caution should be exercised in translating from one species to another65, 66. A recent study 
using human small intestinal organoids cultured from adult stem cells in a variety of different 
media showed infection of enterocytes by SARS-COV and SARS-CoV-260.  Notably, however, 
EECs stained with an antibody for Chromogranin A+ (CGA) were never infected; CGA is 
expressed in all EEC cells, particularly the monoamine containing sub-population67. These 
data contrast with the expression of ACE2 by EECs within human stomach and ileum and 
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with an ability of enteroviruses to infect EECs63, 68. They suggest that the SARS viruses are 
unlikely to enter EECs to cause GI disturbances by directly stimulating the release of 
hormones from these cells. However, key experiments remain. For example, might the EECs 
of the organoid differ in some way from the native EEC, preventing viral entry? Nevertheless, 
if confirmed, it seems that the induction of enterocyte apoptosis and the rapidly increasing 
inflammatory and immune cell milieu surrounding the EECs (measured as increased mRNA 
for cytokines and interferon stimulated genes)60 will secondarily induce the release of 
hormones from the embedded EECs (69 for mechanisms). 
 In addition, gut microbiota have been implicated in modulation of gut inflammation70 but as 
yet, it is unclear how changes in gut microbiota during SARS-CoV-2 infection may contribute 
to the generation of symptoms. For example, a pilot study of the faecal microbiome in 
hospitalized patients showed an association between changes in the microbiota, faecal 
levels of SARS-CoV-2 and the severity of respiratory symptoms71. However, only one of the 
patients reported GI symptoms (diarrhoea before admission) and none during admission. 
Microbiota were included in a model of SARS-CoV-2-induced diarrhoea10. This is of particular 
relevance as ACE2 has been implicated in the regulation of the gut microbiome and 
susceptibility to colitis72.  
Finally, we should not overlook the impact of viral-induced digestive tract damage, loss of 
integrity and release of an “inflammatory soup” on infection, resulting in sensitization of 
vagal afferents via receptors for diverse agents including cytokines, prostaglandins, amines 
and purines. There is limited mechanistic data on cytokine-induced emesis. One study in the 
cat showed that intramuscular injections of IL-2 induced emesis after the area postrema was 
ablated, providing indirect evidence for a peripheral action73, but in rat area postrema cells 
IL-1β increased Ca++ influx74. A  more recent study of the cytokine GDF15 favours a central 
action40. Activation of prostanoid receptors on vagal nerve terminals represents an 
additional pathway shown to induce vomiting75. 
An observation of potential therapeutic relevance comes from a study with the NK1 receptor 
antagonist aprepitant in patients with HIV76. NK1 antagonists are used to treat cancer 
chemotherapy-induced emesis by both central and peripheral actions with interactions 
between the 5-HT3 and the NK1 receptor34, 46. In HIV patients, aprepitant administered over 2 
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weeks reduced plasma concentrations of cytokines (G-CSF, IL-6, IL-8, TNFα) with in vitro and 
pre-clinical studies in non-human primates providing additional evidence for anti-retroviral 
and anti-inflammatory effects. Overall, this combination of actions of aprepitant together 
with the anti-emetic activity46 may make the drug worthy of investigation in COVID-19 
patients particularly as aerosolised vomit is a viral vector44. 
Further studies are required to investigate the presence of ACE2 and TMPRSS2 in the various 
sub-populations of EEC cells (particularly EC cells)77, 78. Additionally, it should be noted that 
many of the GI hormones capable of inducing nausea and vomiting can also reduce appetite 
and food intake (e.g. CCK, GLP-1) by acting on the area postrema and hypothalamic 
circumventricular organs, so may also relate to the appetite suppression reported on 
admission in a few studies, but at a relatively high incidence16, 31. 
Finally, although attention has focused on the intestinal epithelium the early human studies 
reported the presence of ACE2 in the smooth muscle cells of the muscularis mucosa and 
muscularis propria, and the vascular smooth muscle and endothelium in the stomach, small 
intestine and colon54. This does not necessarily mean that SARS-CoV-2 gains entry into the 
muscle cells as additional binding to a chemokine co-receptor may be needed. Nevertheless, 
further studies are needed to assess whether actions of SARS-CoV-2 on GI smooth muscle 
could be involved in the pathophysiology of GI symptoms. The presence of ACE2 (and 
TMPRSS2) in these locations requires study using current molecular techniques and 
functional studies using in vitro pharmacological models79 to assess whether actions of 
SARS-CoV-2 on GI smooth muscle could be involved in symptom generation. For example, 
changes in GI motility may be involved in COVID-19 diarrhoea, described more as an 
increase in stool frequency rather than liquidity16 so may not be (completely) of epithelial 
origin. 
3. ACE2 in the gut-brain axis, viral entry, nausea and vomiting by central actions of 
SARS-CoV-2 
As the COVID-19 pandemic has progressed there has been increasing awareness of the 
central nervous system as a target, with some authors including nausea, vomiting and 
headache as “neurologic signs”80. There is pre-clinical data showing ACE2 expression in the 
brain notably in the nucleus tractus solitarius and the area postrema81 and more limited 
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evidence for the presence of ACE2 in the brain82, 83. The view that SARS-CoV-2 can access the 
brain via the blood (the circumventricular organs where the blood-brain barrier is relatively 
permeable being assumed to be particularly vulnerable) or by neuroinvasion via the vagal 
afferents (which supply both the lungs and the digestive tract) is growing in strength82, 84, 85; 
SARS-CoV is neuroinvasive and has been detected in human brain86.  Whilst the vagal 
transport of SARS-CoV-2 is unlikely to account for acute onset of nausea and vomiting, 
access of the virus to the NTS and more directly via the area postrema is a potential 
mechanism by which later nausea and vomiting may be induced and a pathway by which 
regulation of breathing and blood pressure can be compromised. Vomiting is a key symptom 
of  porcine haemagglutinating encephalomyelitis coronavirus which can access the brain 
stem, but it must be noted that it has not been determined if this effect is due to a central 
(e.g. NTS) or peripheral effect87. 
Viral damage to the dorsal brain stem which has a major role in regulation of digestive tract 
function could contribute to the development of post-viral digestive tract symptoms (e.g. 
gastroparesis) which may emerge during recovery.  
Are there lessons to be learnt for the digestive tract from the interactions between SARS-
CoV and ACE2 in the respiratory system? 
The interactions between SARS-CoV, ACE2 and the respiratory epithelium in the 
pathogenesis of acute respiratory distress syndrome (ARDS)/ acute lung injury (ALI), has a 
number of lessons for  understanding the effects of SARS-CoV-2 on the digestive tract (for 
reviews see88, 89. The key observations in the airways, mostly from mice studies are: i) ACE2 
is protective against ALI by its conversion of angiotensin II (AII) to angiotensin (1-7) and 
angiotensin I to angiotensin (1-9), with severe ARDS in Ace2 KOs being improved by 
administration of an angiotensin 1 receptor (AT1) antagonist; ii) Once initiated the severity of 
ARDS is influenced by ACE2 and other components of the renin-angiotensin system (RAS); iii) 
Ace2 KOs are resistant to SARS-CoV; in wild-type mice SARS-CoV downregulates ACE2 in the 
lungs with consequent elevation of AII levels, also reported in patients with ARDS90. These 
studies give  insights into viral effects on the lungs but as the studies were  in mice which do 
not vomit51, 52 the effect of ACE2 KO on vomiting is unknown. 
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The presence of ACE2 and SARS-CoV-2 in  digestive tract epithelium and the superficial 
similarities between airways and the digestive tract, including the presence of EECs linked to 
the vagus91, enables speculation on the effects of ACE2 and SARS-CoV-2 interactions in the 
digestive tract in relation to nausea and vomiting. 
a) SARS-CoV-2 infection in the digestive tract causes inflammatory damage, with 
consequences for induction of nausea and vomiting, discussed above. The 
inflammatory effects are local and systemic. In human ARDS plasma IL-6 increases 
and interestingly treatment with recombinant human ACE2 showed a trend to 
decrease IL-690 an effect if repeated in COVID-19 patients may be beneficial to the 
digestive tract as well as any effects of cytokines on nausea, vomiting and food 
intake. 
b) Interaction between SARS-CoV-2 and ACE2 in both the respiratory and digestive 
tracts will elevate plasma AII concentrations; in patients the average concentration of 
plasma AII is ~3x higher than in healthy subjects with an average concentration of 
~300pg/ml92. In pre-clinical studies AII has been shown to induce emesis when given 
intravenously and into the cerebral ventricles93, 94 and to increase neuronal activity in 
the area postrema95-97 with AT1 receptors implicated. This provides a plausible 
mechanism by which elevated plasma AII in COVID-19 could induce nausea and 
vomiting, providing an additional trigger to those from the GI tract (Figure 2).  There 
is also pre-clinical evidence that systemic AII can have central effects to suppress 
respiration which are not dependent upon the integrity of the AP98.  Circulating AII 
can also affect gastric and intestinal motility and could contribute the genesis of 
nausea (and diarrhoea).The EC50 for contraction of the human small intestine in vitro 
was 1.5x10-8 M99, a concentration less than the average of ~300pg/ml reported in 
COVID-19 patients92 which equates to ~3x10-7 M and an earlier study reported 
contraction of gastric muscle with a threshold concentration of AII of 10-9 M100. 
c) Angiotensin 1 and 2 receptors are found throughout the digestive tract and modulate 
smooth muscle activity as well as epithelial secretion and absorption101. Actions of 
elevated AII could influence any of these functions with motility changes most likely 
to be implicated in nausea and abdominal pain (these could also involve local 
vasoconstriction) and both motility and epithelial transport in pathogenesis of 
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diarrhoea. Understanding the digestive tract effects of SARS-CoV-2 will require a 
detailed understanding of the RAS in the human digestive tract. 
Possible role of medications and co-existing morbidities in nausea and vomiting in COVID-
19 patients. 
The above sections have focused on the direct effects of SARS-CoV-2 on the digestive tract 
as the most likely cause of nausea and vomiting. However, two other potential causes need 
to be recognized briefly for completeness. Firstly, prior to presentation at hospital patients 
may be prescribed medications which may have nausea and vomiting as side effects. Of 
particular relevance are ACE inhibitors for treatment of hypertension (e.g. lisinopril) and 
anti-diabetic drugs (e.g. metformin, liraglutide). Hospitalized patients being treated for 
COVID-19 may be treated with cytokine modulators, anti-biotics and anti-viral agents which 
may have nausea as a side -effect and should be considered when assessing the incidence of 
nausea. One publication reported that the incidence of nausea and vomiting did not differ 
whether patients did or did not receive either antibiotics or antiviral treatments4. Secondly,  
nausea and vomiting may be secondary to damage outside the upper digestive tract. 
Although the lungs and airways might seem an obvious site given particularly considering 
their vagal afferent innervation, there is no evidence that nausea or vomiting can be induced 
from the airways. However, there is pre-clinical evidence that activation of respiratory 
system vagal afferents can block induction of vomiting102. Renal failure is also a symptom of 
severe COVID-19 and in other settings nausea and vomiting can be symptoms with the 
mechanism not defined, although it is unlikely to be due to renal afferents103. The liver is 
also damaged in severe COVID-19 and although it has a vagal afferent supply projecting to 
the brainstem104 there is no evidence implicating the afferents directly in nausea and 
vomiting105. It is likely that nausea and vomiting associated with hepatic failure is due to loss 
of the detoxifying function of the liver. Cardiac failure also occurs in severe cases of COVID-
19. Ventricular cardiac afferents in the cat have been shown to be capable of inducing 
vomiting and are thought to be responsible for the nausea and vomiting  associated with a 
myocardial infarct106 so could provide a pathway for their induction in cardiac failure. 
Therapeutic opportunities 
Optimal anti-emetic treatment relies on an understanding of the pharmacology of the 
pathways involved. Based on our hypothesized mechanisms described above we would 
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expect the combination of a 5-hydroytryptamine3 (e.g. ondansetron, palonosetron) and a 
neurokinin1 receptor antagonist (e.g. aprepitant) to be effective as they would block at the 
peripheral site of activation/sensitization of vagal afferents and central sites in the dorsal 
brain stem (nucleus tractus solitarius/ area postrema)46. It is interesting to note that the 
synthetic corticosteroid dexamethasone is being used to treat the inflammatory actions 
effects of SARS-CoV-2 but the use of dexamethasone as an anti-emetic may not be widely 
known outside the oncology community. In the treatment of the intense nausea and 
vomiting associated with some anti-cancer chemotherapy regimes dexamethasone has been 
used for 40 years107 in conjunction with more classical anti-emetics (e.g., metoclopramide, 
ondanseton, aprepitant)34, 46 where it enhances their efficacy with a particular improvement 
in nausea  (see 34, 46, 108 for refs). The anti-emetic effect of dexamethasone has been ascribed 
to its anti-inflammatory effect on the intestinal epithelium as its efficacy is greater in the 
delayed phase of chemotherapy-induced emesis where inflammatory damage releasing 
systemic mediators acting on the area postrema has been implicated46. However, there has 
been little formal research on the mechanism(s) underlying the anti-emetic effects of 
dexamethasone but such studies may provide additional insights into its effects on the 
digestive tract in COVID-19. 
The provision of anti-emetics to patients presenting with nausea will help alleviate this 
unpleasant symptom, reduce the probability that the patient will vomit, but if vomiting is 
present they will reduce it and the associated potential viral spread by aerosolization in 
vomit. 
Concluding comments 
This review has highlighted nausea and vomiting as acute symptoms of COVID-19 with a 
focus on incidence of occurrence (Figure 1) and on mechanisms (Figure 2).  The literature we 
reviewed shows the incidence of nausea ranges from 1-30 % but with a median incidence of 
10.5%, similar to that of diarrhea but less than that of vomiting (7%). A systematic review 
and meta-analysis of the incidence of nausea and vomiting as separate symptoms in COVID-
19 is needed.  However, many studies do not report nausea and although more report 
vomiting it is not clear if this represents difference in data collection methodology. We argue 
that there should be a greater focus on collecting data on nausea as it may be a more 
sensitive early marker of digestive tract infection (i.e. prior to fever and cough and probably 
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preceding diarrhoea) in addition to representing a neglected symptom with a particular 
potential to be overlooked in children. The absence of diagnostic biomarkers for nausea is an 
additional challenge108.  A possible mechanism is discussed whereby nausea and vomiting 
can be initiated by SARS-CoV-2 within the blood acting directly on brainstem structures. We 
also propose that the EECs may be a target for SARS-CoV-2 responsible (in part) for the 
pathogenesis of nausea and vomiting; these proposals require further testing using available 
techniques and may give insights into supportive treatments (e.g., 5-HT3 and NK1 receptor 
antagonists). Further studies of mechanisms are needed and in addition to in vitro studies of 
EEC cell lines these may include studies in the ferret which is sensitive to SARS-CoV-2109 and 
which is an established animal model for the study of emetic mechanisms and anti-emetic 
pharmacology110. The incidence of nausea/vomiting and diarrhoea in COVID-19 is lower than 
in SARS but the SARS-CoV-2 protein spike is 10-20x more potent at binding ACE2 compared 
to SARS111 so a comparison of the effects on different cell populations in the GI epithelium 
may provide an insight into the reasons. The brain stem as a site at which mediators from 
the digestive tract induce nausea and vomiting and loss of appetite is discussed. Finally, as 
the majority of patients who develop COVID-19 recover, the potential development of post-
infection functional bowel disorders112 needs to be monitored, where nausea and vomiting 
may also be symptoms. Thus, the recognition of nausea and vomiting as key symptoms 
should lead to greater understanding of how SARS-CoV-2 attacks the GI tract and brainstem 
so preventative measures can treat the symptoms and limit the spread of the virus by 
vomiting. 
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Figure 1. The incidence of nausea and/or vomiting and diarrhoea from 41 clinical studies1, 2, 
4, 5, 16, 22-28, 30, 31, 35, 36, 41, 42, 92, 113-134 :nausea, n=34; vomiting, n=39; diarrhoea, n=39. Values for 
individual studies are shown together with the median and 95% confidence intervals. No 
distinction was made between nausea and vomiting in 10 studies so the same incidence was 
used in both categories. The total number of patients in the studies was 12239. Five studies 
(data indicated by triangles) reported only data on children (1.5 months to 17 years) 28, 42, 114, 
115, 128. 
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Figure 2. Diagram summarising the potential mechanisms by which SARS-Co-V-2 could 
induce nausea and vomiting. The left-hand panel shows the routes by which virus can enter 
the body to access the airways and digestive tract. Air can enter the digestive tract during 
swallowing. The presence of high levels of angiotensin converting enzyme 2 receptor in the 
airways and digestive tract is indicated by red lines. The middle panel shows the potential 
mechanisms (based on evidence discussed in the text) for the interaction of the virus with 
the digestive tract epithelium leading to release of neuroactive agents from enteroendocrine 
cells and inflammatory mediations which act either by stimulating/sensitising abdominal 
vagal afferent terminals and /or act on the area postrema in the dorsal medulla where the 
blood brain and blood cerebrospinal fluid barriers are relatively permeable. In addition, 
angiotensin II levels may increase and have central actions together with virus which may 
enter the circulation from damaged lungs and digestive tract epithelia, The right hand panel 
summarises  the consequences of vagal afferent and area postrema activation to induce 
nausea and vomiting by projection of information to higher brain regions (nausea and 
anorexia) and  vomiting by motor pathways in the ventral brainstem and spinal cord. 
Abbreviations: ACE 2: angiotensin converting enzyme receptor 2; AP: area postrema; NTS: 
nucleus tractus solitarius; DMVN: dorsal motor vagal nucleus; VRG: ventral respiratory group 
of neurones; EEC; enteroendocrine cells in the digestive tract; GLP-1: glucagon-like peptide-
1; CCK: cholecystokinin; IL-6: interleukin-6; TMPRSS2:transmembrane protease serine 2; 5-
HT: 5-hydroxytryptamine. 
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